Investors.

In November 2007 and in December 2009, Skyline Diagnostics completed two financing rounds. The current shareholders are Erasmus MC Biomedical Fund, LSP and Vesalius Biocapital.

Click here for more information for investors.

  • Information for investors

    Skyline Diagnostics is definitely changing the diagnostic, prognostic and treatment landscape in hematologic cancer diagnostics. The company operates in a market characterized by substantial technical and regulatory entry barriers. Multiple growth drivers, led by the revolutionary AMLprofiler™, allow the company to develop considerable value in the large and well-defined hematological...

    Read more >>

  • Erasmus MC Biomedical Fund

    The Erasmus MC Biomedical Fund is an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Rotterdam region. The fund targets companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology,...

    Read more >>

  • LSP

    LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry.

    Read more >>

  • Vesalius Biocapital

    Vesalius focuses on the creation, financing and growth of early-stage life science companies. The managed Vesalius funds invest in areas with a high unmet medical need and a significant profit potential: new therapeutics, cutting-edge medical devices, innovative drug delivery technologies and diagnostic tests and instruments with a high utility level.

    Read more >>

Dr. Molewaterplein 50, Suite Ee1971, 3015 GE Rotterdam. The Netherlands, Europe. Phone: +31 (0)10 7038410. Fax: +31 (0)10 7043076. E-mail: info@skyline-diagnostics.com